Insulin Aspart Sanofi (Insulin Aspart)

Insulin Aspart is a rapid‑acting insulin analog that lowers blood glucose by facilitating cellular uptake.

• Type 1 diabetes mellitus: provides mealtime glucose control to match carbohydrate intake.
• Type 2 diabetes mellitus: assists in post‑prandial glucose reduction when oral agents are insufficient.
• Gestational diabetes mellitus: can be used under specialist supervision to achieve target glycaemia during pregnancy.

• Insulin Aspart binds to the insulin receptor on cell membranes, triggering autophosphorylation and activation of intracellular signaling cascades such as the PI3‑K/Akt pathway. This promotes translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake in muscle and adipose tissue, while suppressing hepatic gluconeogenesis and glycogenolysis, resulting in lowered plasma glucose levels.

Adverse reactions may occur with any insulin therapy.

Common Side Effects

• Hypoglycaemia: low blood sugar episodes, especially if meals are missed or dosing is excessive.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Lipodystrophy: localized fat tissue changes with repeated injections.
• Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects

• Severe hypoglycaemia with neuroglycopenic symptoms requiring emergency assistance.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Hypersensitivity to excipients causing systemic symptoms.
• Insulin antibody formation that may alter drug efficacy.

Insulin Aspart requires careful monitoring and patient education.

• Dose adjustment: tailor dose based on blood glucose monitoring and carbohydrate intake.
• Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar.
• Renal impairment: may need dose modification in severe kidney disease.
• Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with several drug classes, affecting glucose control.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycaemia symptoms and prolong its duration.
• MAO‑A inhibitors: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely)

• Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect; monitor blood glucose closely.
• Corticosteroids: may raise blood glucose, requiring insulin dose adjustments.
• Thiazide diuretics: can cause hyperglycaemia, necessitating closer monitoring.